Biren Amin
Stock Analyst at Piper Sandler
(1.90)
# 3,062
Out of 4,761 analysts
52
Total ratings
39.13%
Success rate
-9.47%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Biren Amin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPX Compass Therapeutics | Initiates: Overweight | $12 | $2.92 | +310.96% | 1 | Feb 19, 2025 | |
| VKTX Viking Therapeutics | Maintains: Overweight | $74 → $71 | $34.07 | +108.39% | 2 | Feb 6, 2025 | |
| CRGX CARGO Therapeutics | Downgrades: Neutral | $34 → $4 | $3.77 | +6.10% | 3 | Jan 30, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Initiates: Overweight | $35 | $8.18 | +327.87% | 1 | Dec 2, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Overweight | $200 → $182 | $106.28 | +71.25% | 5 | Nov 27, 2024 | |
| IMNM Immunome | Maintains: Overweight | $23 → $21 | $9.52 | +120.59% | 3 | Nov 14, 2024 | |
| ALLO Allogene Therapeutics | Maintains: Overweight | $11 → $9 | $2.17 | +314.75% | 2 | Nov 14, 2024 | |
| ACLX Arcellx | Maintains: Overweight | $91 → $115 | $63.75 | +80.39% | 2 | Nov 8, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $40 → $32 | $27.52 | +16.28% | 2 | Nov 6, 2024 | |
| BBIO BridgeBio Pharma | Initiates: Overweight | $46 | $36.85 | +24.83% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $7 → $3 | $3.32 | -9.64% | 1 | Jul 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $5.78 | +246.02% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 | $7.00 | +114.29% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $10 | $0.61 | +1,546.36% | 1 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $70 | $2.32 | +2,917.24% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $0.41 | +12,396.94% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $6.69 | +258.74% | 1 | Oct 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $1.61 | +2,011.80% | 1 | Oct 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $1,050 → $500 | $6.64 | +7,430.12% | 2 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $4.60 | +204.35% | 1 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $657 → $691 | $700.33 | -1.33% | 2 | Jun 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 → $10 | $0.78 | +1,182.05% | 1 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $4.08 | - | 4 | Dec 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $101 | $18.59 | +443.30% | 1 | Nov 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $120.69 | -42.83% | 1 | Oct 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $155 | $484.24 | -67.99% | 5 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $136 | $1.82 | +7,372.53% | 4 | Mar 6, 2017 |
Compass Therapeutics
Feb 19, 2025
Initiates: Overweight
Price Target: $12
Current: $2.92
Upside: +310.96%
Viking Therapeutics
Feb 6, 2025
Maintains: Overweight
Price Target: $74 → $71
Current: $34.07
Upside: +108.39%
CARGO Therapeutics
Jan 30, 2025
Downgrades: Neutral
Price Target: $34 → $4
Current: $3.77
Upside: +6.10%
Corbus Pharmaceuticals Holdings
Dec 2, 2024
Initiates: Overweight
Price Target: $35
Current: $8.18
Upside: +327.87%
Sarepta Therapeutics
Nov 27, 2024
Maintains: Overweight
Price Target: $200 → $182
Current: $106.28
Upside: +71.25%
Immunome
Nov 14, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $9.52
Upside: +120.59%
Allogene Therapeutics
Nov 14, 2024
Maintains: Overweight
Price Target: $11 → $9
Current: $2.17
Upside: +314.75%
Arcellx
Nov 8, 2024
Maintains: Overweight
Price Target: $91 → $115
Current: $63.75
Upside: +80.39%
Apellis Pharmaceuticals
Nov 6, 2024
Maintains: Neutral
Price Target: $40 → $32
Current: $27.52
Upside: +16.28%
BridgeBio Pharma
Sep 4, 2024
Initiates: Overweight
Price Target: $46
Current: $36.85
Upside: +24.83%
Jul 19, 2024
Downgrades: Hold
Price Target: $7 → $3
Current: $3.32
Upside: -9.64%
Jun 21, 2024
Reiterates: Overweight
Price Target: $20
Current: $5.78
Upside: +246.02%
Jun 21, 2024
Maintains: Overweight
Price Target: $15
Current: $7.00
Upside: +114.29%
May 31, 2024
Initiates: Overweight
Price Target: $10
Current: $0.61
Upside: +1,546.36%
May 19, 2023
Maintains: Buy
Price Target: $120 → $70
Current: $2.32
Upside: +2,917.24%
Jan 11, 2021
Initiates: Buy
Price Target: $51
Current: $0.41
Upside: +12,396.94%
Oct 30, 2020
Initiates: Buy
Price Target: $24
Current: $6.69
Upside: +258.74%
Oct 19, 2020
Initiates: Buy
Price Target: $34
Current: $1.61
Upside: +2,011.80%
Sep 14, 2020
Downgrades: Hold
Price Target: $1,050 → $500
Current: $6.64
Upside: +7,430.12%
Jul 24, 2020
Initiates: Buy
Price Target: $14
Current: $4.60
Upside: +204.35%
Jun 12, 2020
Maintains: Buy
Price Target: $657 → $691
Current: $700.33
Upside: -1.33%
Jun 1, 2020
Downgrades: Hold
Price Target: $16 → $10
Current: $0.78
Upside: +1,182.05%
Dec 11, 2017
Upgrades: Buy
Price Target: n/a
Current: $4.08
Upside: -
Nov 9, 2017
Initiates: Buy
Price Target: $101
Current: $18.59
Upside: +443.30%
Oct 3, 2017
Maintains: Buy
Price Target: $66 → $69
Current: $120.69
Upside: -42.83%
Jul 11, 2017
Initiates: Buy
Price Target: $155
Current: $484.24
Upside: -67.99%
Mar 6, 2017
Initiates: Buy
Price Target: $136
Current: $1.82
Upside: +7,372.53%